Search Results

Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch® technology, has today announced a new £2 million investment

Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.

Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK.

Medherant has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.

The award recognises Medherant’s rapid progress and innovation in the development of next-generation transdermal drug delivery patches.

Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients

This latest investment will support the company as it progresses its ibuprofen TEPI Patch into clinical development in early 2018.